The incidence of long-term oral complications after hematopoietic SCT (HSCT) varies between 60 and 100%. The aim of this study was to compare the salivary secretion rate and the contribution of known risk factors for a low salivary secretion rate 1 year after HSCT in children conditioned with fractionated TBI (fTBI) and in children conditioned with single-dose TBI (sTBI). The study involved 44 patients, 27 conditioned with sTBI and 17 conditioned with fTBI. The unstimulated and stimulated salivary secretion rates (USSRs and SSSRs) were estimated before HSCT and at 1-year follow-up. Risk factors that may have influenced the salivary secretion rate were recorded. An SSSR of p0.5 mL/min and a USSR of p0.1 mL/min were chosen as cut-off points for salivary dysfunction. The median reduction in stimulated salivary flow 1 year after HSCT was 56% in the sTBI group and 12% in the fTBI group (P ¼ 0.003). The median reduction in unstimulated salivary flow 1 year after HSCT was 74% in the sTBI group and 33% in the fTBI group (P ¼ 0.003). In the multivariate model, a significant correlation between both sTBI (odds ratio (OR) ¼ 6.49, 95% confidence interval (CI) ¼ 1.40-30, P ¼ 0.014) and seropositivity of the recipient for 3-4 herpesviruses (OR ¼ 6.57, 95% CI ¼ 1.26-34, P ¼ 0.021) and a low stimulated salivary secretion rate (o0.5 mL/min) was found 1 year after HSCT.
Introduction
Allogeneic hematopoietic SCT (HSCT) is a well-established treatment for several malignant and non-malignant disorders. [1] [2] [3] Approximately 50% of the patients become long-term survivors. 4 The success of HSCT is limited by infections during the neutropenic phase, GVHD and relapse. 5 The most commonly used myoablative therapies in the preparation of patients for HSCT are CY combined either with TBI or with BU. [6] [7] [8] For patients with ALL, irradiation is preferred instead of BU due to the lower risk of relapse. 9 Apart from acute toxicity, TBI may induce late toxic effects including endocrinological disturbances, pneumonitis, cataract, secondary malignancies and, in children, reduced growth and dental abnormalities. 10, 11 Previously, TBI was administered in one single-session total body irradiation (sTBI), but fractionated radiation over several days (fTBI) is currently preferred. 12 When fTBI is used, the total dose of radiation can be increased compared with sTBI. The larger total dose achieved with fTBI allows greater killing of malignant cells, whereas the lower doses per fraction reduce the late normal tissue morbidity, resulting in a reduction of negative side effects. 13 The incidence of long-term oral complications in HSCT patients varies between 60 and 100%. 14, 15 The conditioning regimen used also has an influence on the occurrence of secondary orofacial complications such as impaired root development, enamel hypoplasia, microdontia, dental aplasia, temporomandibular dysfunction and salivary dysfunction. 16, 17 It has been shown that children conditioned with sTBI and CY have reduced salivary function 1 year after HSCT. 16, 18, 19 In a longitudinal study of salivary function, it was found that children conditioned with TBI/CY had a significantly lower stimulated whole-saliva secretion rate 4 years after HSCT than children conditioned with chemotherapy only. 20 No further increase in salivary flow was seen 2 years after HSCT, indicating that there may be a permanent reduction in salivary function in children conditioned with sTBI/CY. 20 Significant risk factors for a low stimulated salivary secretion rate 1 year after HSCT are sTBI, female sex and seropositivity for 3-4 members of the herpesvirus family. 21 The hypothesis to be tested in this paper was that children conditioned with fTBI would have a significantly better salivary secretion rate 1 year after HSCT than those conditioned with sTBI. A secondary aim was to investigate the contribution of other known risk factors for low salivary secretion rate 1 year after HSCT.
Materials and methods

Patients
The study involved 44 children who were recipients of allogeneic HSCT and who were grafted between January 1994 and December 2005. Children over 4 years of age were considered able to co-operate with salivary sampling during the follow-up. A total of 165 children less than 13 years of age received allogeneic HSCT at Karolinska University Hospital, Huddinge during this period. A total of 57 children died during the first year, with no significant difference in distribution between the conditioning groups. In all, 54 children were too young to cooperate in the salivary secretion test and 10 other children received other types of conditioning therapy that did not include radiotherapy.
The children were divided into two groups: those who received sTBI and those who received fTBI in combination with various cytotoxic therapies, depending on the diagnosis (Table 1 ). Before 1998, fTBI was seldom used. The baseline characteristics of the patients are presented in Table 1 .
Conditioning sTBI (10 Gy) with the lungs shielded to receive no more than 9 Gy in combination with CY 60 mg/kg for 2 days was given to 24 patients. Three other patients received the sTBI/ CY protocol with the addition of etoposide 300 mg/m 2 . fTBI, 3 Gy Â 4, to a total dose of 12 Gy on 2 days and Cy 60 mg/kg for 2 days were given to 14 patients, with the addition of etoposide or Ara-c in two of these patients. Three patients received a reduced-intensity conditioning protocol consisting of Fludarabine 30 mg/m 2 for 3 days, fTBI 2 Â 3 Gy and Cy 60 mg/kg for 2 days.
Patients with an unrelated donor, an HLA-mismatched donor or severe aplastic anemia (SAA) were also given antithymocyte globulin (ATG) 2 mg/kg/day for 3-5 days. Most of the patients received Thymoglobulin, but a few received ATG-Fresenius or OKT-3 (Table 1 ).
Donor matching
There were 22 HLA-A, -B and -DR matched unrelated donors (MUDs) and 12 HLA-identical sibling/related donors. In 10 cases, an allele or Ag-mismatched unrelated donor was used (Table 1) .
Immunosuppressive prophylaxis MTX, CsA or both was used as prophylaxis against GVHD in most patients. Three patients received sirolimus and tacrolimus. One patient was given CsA and steroids, and three patients were given a T-cell-depleted graft (TcD) plus CsA and MTX.
Treatment of GVHD Treatment of acute GVHD consisted of prednisolone 2 mg/kg/day over 1 week and was tapered depending on response. In more severe cases, a booster dose of methylprednisolone 0.5 g was used. Treatment of chronic GVHD consisted of steroids and CsA (Table 1) .
Viral serology and prophylaxis
Serology before HSCT for the four commonest members of the herpesvirus family (HSV1, cCMV, VZV and EBV) was analyzed in patients and donors.
In the sTBI group, 19 patients (70%) were seropositive for 3-4 herpesviruses and 8 (30%) were seropositive for 0-2 viruses before HSCT. In the fTBI group, the corresponding values were 11 patients (65%) seropositive for 3-4 herpesviruses and 6 (35%) seropositive for 0-2 viruses. The viral serology of recipients and donors is given in Table 2 .
In the case of HSV, IgG titers of X10 000 or close recurrence of symptoms of HSV infection, the patient received oral acyclovir 200 mg Â 4 per day as prophylaxis from the start of conditioning until achieving a neutrophil blood cell count of 40.5 Â 10 9 /L. In the case of severe oral mucositis, the treatment consisted of 5 mg/kg Â 3 per day i.v.
Unstimulated and stimulated salivary secretion rate
The baseline examination was performed approximately 1 week prior to HSCT, before the start of conditioning. The follow-up examination was 1 year after HSCT. All examinations were performed at the Department of Pediatric Dentistry, Karolinska Institute, Huddinge. The patients were instructed not to eat, drink, put anything in their mouth, or brush their teeth for at least 1 h before the examination. The saliva was collected in a quiet examination room. The aim was to do the examination in the morning, preferably before lunch. Unstimulated whole saliva (USSR) was collected over 10 min. The patients were asked to sit in a passive position and to drool or spit into a collecting vessel. Immediately before the test, they were instructed to swallow any remaining saliva in the mouth. The saliva was allowed to accumulate in the mouth and was collected in the vessel approximately once a minute. The volume was recorded and the USSR was expressed as mL/min. A USSR of r0.1 mL/min was considered low. 21 After a short break, paraffin-stimulated whole saliva (SSSR) was collected for 5 min. The patient was asked to chew a standard piece of paraffin wax without swallowing and to spit the saliva into a collecting vessel. Before the collecting procedure started, the paraffin wax was chewed for 1 min, whereupon the patient was instructed to swallow any saliva that might be in the mouth. The volume was recorded and SSSR was expressed in mL/min. An SSSR of p0.5 mL/min was considered low. 21 
Risk factors
Known possible risk factors for low salivary secretion such as gender, age, GvHD, seropositivity for herpesviruses, sTBI and fTBI were tested in a multivariate analysis against unstimulated and stimulated saliva secretion in patients who had received sTBI or fTBI.
Statistical analysis
Power analysis. With a calculated mean saliva production of 1.0 and 0.4 mL/min (s.d. 0.5) in the two groups, a power of 90% and an a-error of 0.05, we calculated that we would require 16 patients in each group. The logistic regression model was used in univariate analyses of possible risk factors that might contribute to a low salivary secretion rate. A stimulated whole salivary secretion rate of p0.5 mL/min was chosen as cut-off point for salivary dysfunction. Significant variables at the 5% level from the univariate analyses were included in a multivariate logistic regression analysis. Comparisons between groups of patients were performed using Fisher's exact test and the Mann-Whitney U-test.
The protocol for this study was approved by the local ethical committee at Karolinska University Hospital, Huddinge.
Results
Salivary secretion rate
At baseline, there were no significant differences between unstimulated or stimulated salivary secretion rates in the sTBI and fTBI groups (Figures 1a and b) . One year after HSCT, both the unstimulated and stimulated salivary secretion rates were significantly lower in the sTBI group than in the patients who underwent fTBI (Figures 1c  and d) . The median reduction in stimulated salivary flow 1 year after HSCT was 56% (range 0-93%) in the sTBI group, as compared with 12% (0-70%) in the fTBI group (P ¼ 0.003). The median reduction in unstimulated salivary The number of children with a stimulated salivary secretion rate of o0.5 mL/min 1 year after HSCT was 63% (17/27) in the sTBI group, as opposed to 24% (4/17) in the fTBI group (P ¼ 0.015).
Fifteen children in the TBI group and six in the fTBI group were diagnosed as having chronic GVHD. When comparing children with and without cGVHD there was no statistically significant difference in salivary secretion rate.
In univariate logistic regression analysis, the seropositivity of 3-4 herpesviruses of the recipient before transplantation was significantly associated with a low degree of stimulated salivary secretion 1 year after HSCT. None of the viruses examined, HSV, EBV, CMV or VZV, was individually correlated to salivary dysfunction.
In the multivariate model, both sTBI (odds ratio (OR) ¼ 6.49, 95% confidence interval (CI) ¼ 1.40-30, P ¼ 0.014) and seropositivity of recipients for 3-4 herpesviruses (OR ¼ 6.57, 95% CI ¼ 1.26-34, P ¼ 0.021) remained significantly correlated with low stimulated salivary secretion rate (o0.5 mL/min) 1 year after HSCT. The mean unstimulated salivary secretion rates in relation to different risk factors such as seropositivity for 3-4 members of the herpesvirus family and sTBI present are shown in Figure 2a .
There was an inverse relationship between the number of risk factors present and the mean degree of stimulated salivary secretion. With no risk factor present (n ¼ 6), the median SSSR was 1.2 mL/min (0.80-1.75); for one risk factor present (n ¼ 19) median SSSR was 0.67 mL/min (0.08-1.70), and if both risk factors were present (n ¼ 19) it was 0.3 mL/min (0.07-0.80) (Figure 2b ).
Discussion
The results of this study show that children conditioned with sTBI/CY had a significantly reduced salivary secretion rate 1 year after HSCT relative to children conditioned with fTBI/CY. This is the first time that the effect of dose fractionation of TBI on salivary secretion rate has been reported.
In order to give an equivalent degree of engraftment of allogeneic BM, higher total doses of radiation are required with fractionation of TBI compared with administration of a single dose. 22 Studies of TBI in the setting of HSCT have shown that there is an inverse relationship between the intensity of the conditioning regimen on the one hand, and the toxicity, treatment-related mortality and risk of relapse on the other. 23 The optimal dose for TBI in allogeneic HSCT is still to be determined because it depends on many different variables such as patient age, comorbid conditions, disease characteristics, dose rate and fractionation, source and dose of stem cells, and also GVHD prophylaxis. It has been shown that incidence and mortality caused by veno-occlusive disease of the liver are significantly higher with sTBI than in those who receive fTBI. 24 With regard to other side effects, it has been shown that fractionation of TBI reduces the risk of cataract formation. 25 Hyperfractionated TBI given three times a day for 3 days, with a total dose of 14.4 Gy, results in cataract formation in 13% of the patients as compared with 21% in those given 8 Gy of sTBI. Patients given sTBI also had an increased need for eye surgery.
The usual fTBI schedules (12-15 Gy) induce less interstitial pneumonitis than the standard low-dose rate (10 Gy) in sTBI. 26 Oya et al. 27 studied the influence of radiation dose rate and lung dose on interstitial pneumonitis (IP) Fractionated TBI and saliva K Garming Legert et al after fTBI and reported that the cumulative incidence of IP was significantly higher in patients who developed acute parotitis, as indicated by either an elevation in serum amylase level or parotid pain of grade 1 or 2. Generally, the effect of radiation therapy on salivary gland tissue is dependent on how the dose is delivered. A higher dose per fraction, as in TBI with a lower cumulative dose (10-12 Gy), results in less damage to salivary tissue compared with radiation fractionation schemes with lower radiation dose per fraction, but much higher cumulative dose, as in head and neck cancer patients. 28 In patients given high-dose treatment of up to 60 Gy, no recovery of gland function is observed. 29 In a study of acute toxicity during fTBI, Buchali et al. 30 reported that during fractionated doses of 2 Gy given twice daily (with an 8-h interval) over 3 days, symptoms of mild xerostomia (mild mouth dryness, slightly thickened saliva and slightly altered taste) continued to increase up to the sixth fraction, which was 56 h after the first fraction. At the sixth fraction, 30% of the patients exhibited mild xerostomia and there was no recovery during the HSCT procedure. In the present study, evidence of salivary dysfunction was found 1 year after HSCT in 24% of children who received fTBI. We have previously reported that 79% of children receiving sTBI reported at least one or more symptoms of xerostomia 5 years after HSCT. 31 The mechanisms of radiation-induced salivary gland dysfunction are poorly understood. The submandibular/ sublingual and parotid glands differ in radiosensitivity, with the serous parotid glands being more sensitive to irradiation. 32, 33 Radiosensitivity of an organ is usually related to a fast rate of turnover of cells. The cells in the salivary gland have a relatively slow turnover rate. 34, 35 The salivary gland is ranked as one of the most radiosensitive organs in the body. Polypharmacy has also been implicated in salivary dysfunction, but the effect of prescription drugs is usually reversible and the glands retain their secretory ability. 36 In the present study, seropositivity of the recipient for herpesviruses before transplant was also found to be a significant risk factor associated with low stimulated salivary secretion 1 year after HSCT, and with more risk factors present the risk of having a reduced salivary secretion rate 1 year after HSCT was higher. This is in agreement with a previous study showing that TBI, female sex and seropositivity for 3-4 herpesviruses were significant risk factors for developing salivary dysfunction in children 1 year after HSCT. 21 An influence of herpesviruses on the pathogenesis of primary Sjo¨gren's syndrome has been shown in several studies. CMV has also been suggested to be responsible for glandular dysfunction in patients with Sjo¨gren's syndrome. 37 Furthermore, elevated levels of EBV have been found in saliva and salivary glands from patients with Sjo¨gren's syndrome. 38 It is possible that the elevated levels of virus are involved in the destruction of salivary glands. 39 The role of human herpesvirus 6 (HHV-6) in the pathology of salivary glands is not obvious, but the salivary glands have been suggested to be the site of replication of this virus. 40 In our study, seropositivity of the recipient for herpesviruses before transplant was found to be a significant risk factor associated with low stimulated salivary secretion 1 year after HSCT. This indicates that herpesvirus was involved in glandular dysfunction observed in our patients.
Reduced secretion rates due to chronic GVHD cannot be differentiated clinically from those due to radiation during the first 4-9 months after HSCT. 41, 42 In agreement with the results from this study, previous studies in children showed no reduction in salivary secretion rate due to GVHD at the 1-year follow-up. 20 Sicca syndrome is one of the major symptoms of cGVHD, particularly in adults. 43 In these children, sicca syndrome was not a major feature of cGVHD.
In conclusion, the results of this study show that fTBI resulted in significantly less reduction of salivary secretion rate 1 year after HSCT than did sTBI, despite the higher total dose of radiation. A cumulative increase in risk factors resulted in significantly less salivary output. It will also be important to study the effect of changes in conditioning regimens on oral health parameters such as salivary function. Long-term follow-up after HSCT is Stimulated saliva +1 year (mL/min) P <0.001 Figure 2 The mean unstimulated (a) and stimulated (b) salivary secretion rates 1 year after HSCT in relation to the observed risk factors present (sTBI and seropositivity for 3-4 members of the herpesvirus family prior to transplant). 0 ¼ no risk factor present (total 6 patients with fTBI and seropositivity for 0-2 herpesviruses), 1 ¼ one risk factor present (sTBI (27 patients) or seropositivity for 3-4 herpesviruses (11 patients)), 2 ¼ two risk factors present (19 patients with sTBI and seropositivity for 3-4 herpesviruses).
required because children will have permanently reduced salivary function and may require additional preventive measures throughout their lives in order to maintain oral health.
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